CoChat

Echinomycin: The first bifunctional intercalating agent in clinical trials

The DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index.

Abstract

Echinomycin is a quinoxaline antibiotic that was originally isolated from Streptomyces echinatus. Based on its antitumor activity against two i.p. implanted murine tumors, the B16 melanoma, and the P388 leukemia, it was brought into clinical trials by the National Cancer Institute. Recent studies on its cytotoxic action have related its antitumor activity with its ability to bifunctionally intercalate with double stranded DNA. Toxicologic studies were carried out in CDF1 mice and beagle dogs using intravenous injections. For the mice studies the dose ranges were 288-692 mcg/kg (864-2076 mcg/m2) by single bolus, and 112-254 mcg/kg/day (336-762 mcg/m2/day) for five consecutive days. In the dog, dose ranges studied were 8.9-89.4 mcg/kg (178-1788 mcg/m2) by single bolus, and 3.4-33.5 mcg/kg/day (68-670 mcg/m2/day) for five consecutive days. The major toxic effects were found in the gastrointestinal, hepatic, and lymphoreticular systems. These were reversible at all but the highest dose, in dogs that had been treated for five consecutive days. Phase I clinical trials using various intravenous schedules were sponsored by the National Cancer Institute. Nausea, vomiting, reversible liver enzyme abnormalities, and allergic reactions were the most common toxicities encountered. Based on results from these studies, the National Cancer Institute has recently begun phase II trials in a broad range of diseases. These trials will further characterize echinomycin's toxic effects and its anti…

Overview

Integrity signals

Registry

Crossref · 10.1007/bf00170766

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 2

  1. Bhatia MC, Thyagarojan TR, Srivastova OP, Anand N, Vora VC: Quinoxaline antibiotics from a Streptomyces species. Indian J Chem 1:277–278, 1963
  2. Katagiri K, Sugiura K: Antitumor action of the quinoxaline antibiotics. Antimicrob Agents Chemother, (1961): pp. 162–168, 1961

Cited by

See all 61

Metadata

Authors
Foster, B. J., Clagett-Carr, K., Shoemaker, D. D., Suffness, M., Plowman, J., Trissel, L. A., Grieshaber, C. K., & Leyland-Jones, B.
Affiliations
National Cancer Institute (US)
Venue
Investigational New Drugs
Published
1985-12
Volume
3
Issue
4
Pages
403-410
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2013828999
Cited by
61
References
18
Citations by year
2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 1
FWCI
0.44
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Investigational New Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
Keywords
echinomycin, quinoxaline antibiotics, anticancer activity, B16 melanoma, P388 leukemia, dose-limiting toxicity, gastrointestinal toxicity, hepatotoxicity, intravenous administration, anticancer agents
MeSH terms
Animals, Clinical Trials as Topic, Cross-Linking Reagents, DNA, Dogs, Drug Evaluation, Echinomycin, Humans, Lethal Dose 50, Neoplasms, Experimental, Quinoxalines, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.